Literature DB >> 11506499

Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer.

A F West1, M O'Donnell, R G Charlton, D E Neal, H Y Leung.   

Abstract

Vascular endothelial growth factor (VEGF) mediates neo-angiogenesis during tumour progression and is known to cooperate with the fibroblast growth factor (FGF) system to facilitate angiogenesis in a synergistic manner. In view of this, we have investigated VEGF expression in 67 cases of prostate cancer previously characterized for fibroblast growth factor-8 (FGF-8) expression. Cytoplasmic VEGF staining was detected in malignant cells in 45 out of 67 cases. Cytoplasmic staining was found in adjacent stromal cells in 32 cases, being particularly strong around nests of invasive tumour. Positive VEGF immunoreactivity in benign glands was restricted to basal epithelium. A significant association was observed between tumour VEGF and FGF-8 expression (P = 0.004). We identified increased VEGF immunoreactivity in both malignant epithelium and adjacent stroma and both were found to be significantly associated with high tumour stage (P = 0.0047 and P = 0.0002, respectively). VEGF expression also correlated with increased serum PSA levels (P = 0.01). Among positively stained tumours, VEGF expression showed a significant association with Gleason score (P = 0.04). Cases showing positive VEGF immunoreactivity in the stroma had a significantly reduced survival rate compared to those with negative staining (P = 0.037). Cases with tumours expressing both FGF-8 in the malignant epithelium and VEGF in the adjacent stroma had a significantly worse survival rate than those with tumours negative for both, or only expressing one of the two growth factors (P = 0.029). Cox multivariate regression analysis of survival demonstrated that stromal VEGF and tumour stage were the most significant independent predictors of survival. In conclusion, we report for the first time a correlation of both tumour and stromal VEGF expression in prostate cancer with clinical parameters as well as its correlation to FGF-8 expression. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11506499      PMCID: PMC2364102          DOI: 10.1054/bjoc.2001.1971

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  40 in total

1.  Expression of vascular endothelial growth factor receptors in human prostate cancer.

Authors:  F A Ferrer; L J Miller; R Lindquist; P Kowalczyk; V P Laudone; P C Albertsen; D L Kreutzer
Journal:  Urology       Date:  1999-09       Impact factor: 2.649

2.  Fgf-8 expression in the post-gastrulation mouse suggests roles in the development of the face, limbs and central nervous system.

Authors:  M Heikinheimo; A Lawshé; G M Shackleford; D B Wilson; C A MacArthur
Journal:  Mech Dev       Date:  1994-11       Impact factor: 1.882

3.  Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma.

Authors:  N Weidner; P R Carroll; J Flax; W Blumenfeld; J Folkman
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

4.  Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma.

Authors:  C A Boocock; D S Charnock-Jones; A M Sharkey; J McLaren; P J Barker; K A Wright; P R Twentyman; S K Smith
Journal:  J Natl Cancer Inst       Date:  1995-04-05       Impact factor: 13.506

5.  Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity.

Authors:  M K Brawer; R E Deering; M Brown; S D Preston; S A Bigler
Journal:  Cancer       Date:  1994-02-01       Impact factor: 6.860

Review 6.  Peptide growth factors in the prostate as mediators of stromal epithelial interaction.

Authors:  R L Byrne; H Leung; D E Neal
Journal:  Br J Urol       Date:  1996-05

7.  Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression.

Authors:  M Toi; K Inada; H Suzuki; T Tominaga
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

8.  Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer.

Authors:  Y Takahashi; Y Kitadai; C D Bucana; K R Cleary; L M Ellis
Journal:  Cancer Res       Date:  1995-09-15       Impact factor: 12.701

9.  Prognostic value of vascular endothelial growth factor expression in gastric carcinoma.

Authors:  K Maeda; Y S Chung; Y Ogawa; S Takatsuka; S M Kang; M Ogawa; T Sawada; M Sowa
Journal:  Cancer       Date:  1996-03-01       Impact factor: 6.860

10.  Topography of neovascularity in human prostate carcinoma.

Authors:  J A Siegal; E Yu; M K Brawer
Journal:  Cancer       Date:  1995-05-15       Impact factor: 6.860

View more
  22 in total

1.  Prognostic role of vascular endothelial growth factor in prostate cancer: a systematic review and meta-analysis.

Authors:  Zhu-Qing Liu; Jue-Min Fang; Yuan-Yuan Xiao; Yu Zhao; Ran Cui; Fei Hu; Qing Xu
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers.

Authors:  Henk van der Poel; Laurence Klotz; Gerald Andriole; Abdel-Rahmène Azzouzi; Anders Bjartell; Olivier Cussenot; Freddy Hamdy; Markus Graefen; Paolo Palma; Arturo Rodriguez Rivera; Christian G Stief
Journal:  World J Urol       Date:  2015-06-03       Impact factor: 4.226

Review 3.  Targeting fibroblast growth factor pathways in prostate cancer.

Authors:  Paul G Corn; Fen Wang; Wallace L McKeehan; Nora Navone
Journal:  Clin Cancer Res       Date:  2013-09-19       Impact factor: 12.531

Review 4.  Does true Gleason pattern 3 merit its cancer descriptor?

Authors:  Saiful Miah; Hashim U Ahmed; Alex Freeman; Mark Emberton
Journal:  Nat Rev Urol       Date:  2016-08-17       Impact factor: 14.432

Review 5.  Active surveillance for low-risk prostate cancer.

Authors:  Laurence Klotz
Journal:  Curr Urol Rep       Date:  2015-04       Impact factor: 3.092

6.  Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression.

Authors:  Jianghua Wang; Wendong Yu; Yi Cai; Chengxi Ren; Michael M Ittmann
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

7.  Fast growth associated with aberrant vasculature and hypoxia in fibroblast growth factor 8b (FGF8b) over-expressing PC-3 prostate tumour xenografts.

Authors:  Johanna Tuomela; Tove J Grönroos; Maija P Valta; Jouko Sandholm; Aleksi Schrey; Jani Seppänen; Päivi Marjamäki; Sarita Forsback; Ilpo Kinnunen; Olof Solin; Heikki Minn; Pirkko L Härkönen
Journal:  BMC Cancer       Date:  2010-10-30       Impact factor: 4.430

8.  Inducing endoderm differentiation by modulating mechanical properties of soft substrates.

Authors:  Maria Jaramillo; Satish S Singh; Sachin Velankar; Prashant N Kumta; Ipsita Banerjee
Journal:  J Tissue Eng Regen Med       Date:  2012-09-24       Impact factor: 3.963

9.  Expression of vascular endothelial growth factor in renal cell carcinoma is correlated with cancer advancement.

Authors:  Ching-Chiang Yang; Kang-Chu Chu; Wen-Meng Yeh
Journal:  J Clin Lab Anal       Date:  2003       Impact factor: 2.352

10.  Vascular morphology differentiates prostate cancer mortality risk among men with higher Gleason grade.

Authors:  Meng Yang; Ke Zu; Lorelei A Mucci; Jennifer R Rider; Michelangelo Fiorentino; Steven K Clinton; Massimo Loda; Meir J Stampfer; Edward Giovannucci
Journal:  Cancer Causes Control       Date:  2016-07-05       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.